Achillion Pharmaceuticals, Inc. (ACHN)
-NasdaqGS 7.75 
0.20(2.65%) 4:00PM EDT|After Hours
:
7.78 0.03 (0.39%) 6:07PM EDT
| Prev Close: | 7.55 |
|---|
| Open: | 7.61 |
|---|
| Bid: | 7.74 x 800 |
|---|
| Ask: | 7.78 x 1300 |
|---|
| 1y Target Est: | 14.00 |
|---|
| Beta: | 2.07 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 7.50 - 7.83 |
|---|
| 52wk Range: | 5.42 - 11.36 |
|---|
| Volume: | 1,220,835 |
|---|
| Avg Vol (3m): | 1,134,090 |
|---|
| Market Cap: | 748.31M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.64 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Achillion Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-21-2013 03:30 PMat Seeking Alpha(Tue 5:40PM EDT)
- The Young And Restless Retirement Portfolio: Stay The Courseat Seeking Alpha(Wed, May 15)
- Achillion Appoints Dr. David Apelian as Chief Medical Officer and Expands Clinical Operations TeamGlobeNewswire(Wed, May 15)
- ACHILLION PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Tue, May 14)
- Achillion: Down But Not Out And Progress Being Madeat Seeking Alpha(Fri, May 10)
- Achillion to Present at Three Upcoming Investor ConferencesGlobeNewswire(Thu, May 9)
- ACHILLION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 7)
- Achillion Reports First Quarter 2013 Financial ResultsGlobeNewswire(Tue, May 7)
- Gilead Misses Analysts’ Estimates on Sales of HIV Drugsat Bloomberg(Thu, May 2)
- Oversold Conditions For Achillion Pharmaceuticalsat TheStreet(Thu, May 2)
- Young And Restless Portfolio: BlackBerry Will Be The Catalystat Seeking Alpha(Tue, Apr 30)
- This Week in Biotechat Motley Fool(Sun, Apr 28)
- Large Market Opportunity in HCV Space Due to Unmet Medical Need, Large Reservoir of Patients and Current Standard of CareWall Street Transcript(Fri, Apr 26)
- Tough Day for This Hepatitis C Underdogat Motley Fool(Tue, Apr 23)
- Achillion presents data on ACH-3102 to treat Hepatitis Cat theflyonthewall.com(Tue, Apr 23)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 6,177.95 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.64 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.15 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | -2.48 |
|---|
Business Summary
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally.
View More